新型促尿酸排泄药
本文为叙述性综述,通过MeSH词检索评估新型促尿酸排泄药疗效的2/3期试验。Lesinurad抑制URAT1和OAT4,3期试验显示其联合别嘌醇或非布司他可有效降尿酸且安全性可接受;Arhalofenate同样作用于URAT1和OAT4,2期试验提示其可降低血尿酸并减少痛风发作风险。
要点
- Lesinurad联合别嘌醇或非布司他为有效降尿酸治疗,安全性可接受。
- Arhalofenate在2期试验中提示可降低血尿酸并减少发作风险。
- 抑制URAT1的新药或可覆盖黄嘌呤氧化酶抑制剂应答失败或禁忌者的需求。
核心结论
- 抑制URAT1的新药应覆盖对黄嘌呤氧化酶抑制剂应答失败或有禁忌的痛风患者未被满足的需求。
研究设计与样本
- 使用MeSH词检索评估新型促尿酸排泄药疗效的2/3期试验,对靶向URAT1和/或其他尿酸转运体的新型药物进行叙述性综述。
主要发现
- Lesinurad抑制URAT1和有机阴离子转运体4(OAT4),3期试验显示其联合别嘌醇或非布司他为有效降尿酸治疗,安全性可接受。
- Arhalofenate与URAT1和有机阴离子转运体4相互作用,2期试验提示其可降低血清尿酸水平并减少痛风发作风险。
关键数值与推荐
- 近期指南指出降尿酸治疗的主要手段仍为黄嘌呤氧化酶抑制。
- 部分痛风患者单用黄嘌呤氧化酶抑制剂未能达到预设的5-6 mg/dl目标。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: According to recent guidelines, the mainstay of urate-lowering therapies remains xanthine oxidase inhibition. However, some patients with gout show failure to achieve the predefined target of 5-6 mg/dl with xanthine oxidase inhibitors alone, so alternative drugs are needed. The aim of this study was to review studies of novel drugs targeting uric acid transporter 1 (URAT1) and/or other urate transporters for the management of gout. METHODS: MeSH terms were used to identify phase 2/3 trials assessing the efficacy of novel uricosurics. A narrative review of novel drugs targeting URAT1 and/or other urate transporters for the management of gout is provided. RESULTS: Lesinurad is a recently approved uricosuric that inhibits URAT1 and the organic ion transporter organic anion transporter 4 (OAT4). Phase 3 trials showed that lesinurad, combined with allopurinol or febuxostat, is a potent urate-lowering therapeutic with an acceptable safety profile. Arhalofenate, another emerging uricosuric, also interacts with URAT1 and organic anion transporter 4. Phase 2 trials suggested that it can both lower serum UA levels and reduce the risk of flares. CONCLUSIONS: New drugs inhibiting URAT1 should cover the unmet need for patients with failure to respond or with contraindications to xanthine oxidase inhibitors.
引用
- Bardin T, Richette P. Novel uricosurics. Rheumatology (Oxford). 2018. PMID: 29272511. doi:10.1093/rheumatology/kex433
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。